Grespo is a young biomedical company specialized in preventing and treating diseases of the Central Nervous System (CNS), based on research on the effect of the 2-oxoglutarate substance (2-OX) in the body. A number of studies have demonstrated effects of 2-OX treatment in several disease fields. Grespo’s main target is the central nervous system (CNS) and diseases like Alzheimer and Parkinson.
GRE213 is intended to be used for treatment and health maintenance for people suffering from MCI, Alzheimer, Parkinson and other CNS-related conditions.
The number of diagnosed patients with Alzheimer disease, the largest of the dementia related CNS diseases, is estimated to more than 30 million worldwide 2012, with an expected increase to 50 million in 2025, due to the aging population. The social cost for Alzheimer disease in the USA alone is estimated to exceed 100 billion USD yearly. These numbers do not include the many people concerned with cognitive decline but not diagnosed with disease. Although more than 1000 clinical studies have been performed there are as yet no cures for the disease. All of these facts point to a huge medical need for new treatments related to CNS..
Grespo is active in research on the effects of 2-oxoglutarate on neurodegenerative diseases such as MCI, Alzheimers and similar.
The company’s investors include industrially experienced individuals with a long history of investing in biomedical ventures.
GRE213 is a combination of two active ingredients, both of which have been used in medical treatments for a number of conditions.
GRE 213 has been shown to increase neurogenesis and improve cognitive functions in animal models exhibiting age related degeneration of CNS.
Neurogenesis decreases with age, although it is present throughout the life time. It is impacted by various factors, such as physical activity, learning and exposure to complexity.